跳至主要内容
临床试验/EUCTR2020-001811-26-BE
EUCTR2020-001811-26-BE进行中(未招募)1 期

De-escalation of anti-TNF therapy in adolescents and young adults with IBD with tight faecal calprotectin and trough level monitoring - FREE-study

niversity Medical Center Groningen0 个研究点目标入组 148 人开始时间: 2021年7月22日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
148

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Aged 12-25 years
  • - Diagnosed with luminal Crohn’s disease or ulcerative colitis
  • - Treated with either 8-weekly infliximab or 2-weekly adalimumab
  • - Current anti-TNF agent as first ever anti-TNF agent or prior anti-TNF agent discontinued for reason other than primary non-response or secondary loss-of-response
  • - No previous attempts to lengthen the dosing interval
  • - Three consecutive faecal calprotectin results in the target range (i.e. <250 µg/g for CD patients; <150 µg/g for UC patients) in the previous 6 months or confirmed endoscopic remission within 2 months before study entry (i.e. simple endoscopic score for Crohn’s disease (SES-CD) <3 points; ulcerative colitis endoscopic index of severity (UCEIS) =1 point or Mayo endoscopic subscore =1 point)
  • - Absence of symptoms associated with active IBD (judged by the local IBD-team)
  • - Writeen informed consent granted
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 48
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 100
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Perianal fistula
  • - Presence of ileostomy or ileoanal pouch (as FC cut-off is not validated for small bowel faeces)
  • - Any inflammatory comorbidity, such as rheumatoid arthritis
  • - Current treatment with corticosteroids (prednisone or budesonide)
  • - Current pregnancy

研究者

相似试验